Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma
Open Access
- 13 January 2023
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (5) , 335.e1-335.e8
Abstract
No abstract availableKeywords
Funding Information
- Kite Pharma Inc
This publication has 10 references indexed in Scilit:
- Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncologyExpert Review of Pharmacoeconomics & Outcomes Research, 2018
- Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”Annals of Oncology, 2017
- Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple MyelomaThe Oncologist, 2017
- Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulatorsClinical Pharmacology & Therapeutics, 2015
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphomaBritish Journal of Cancer, 2009
- Analyzing Oncology Clinical Trial Data Using the Q-TWiST Method: Clinical Importance and Sources for Health State Preference Data*Quality of Life Research, 2006
- Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821Journal of Clinical Oncology, 1999